Ferras Alashkar
Overview
Explore the profile of Ferras Alashkar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cappellini M, Glassberg M, Meyers J, Jimenez M, Nham T, Bueno L, et al.
Ther Adv Hematol
. 2024 Dec;
15:20406207241298088.
PMID: 39687487
Background: Beta-thalassemias (BTs) are characterized by deficient or absent synthesis of the beta-globin subunit, leading to anemia. Patient characteristics and treatment patterns in these patients may vary. Objective: This retrospective...
2.
Boll J, Alashkar F, Aramayo-Singelmann C, Hoferer A, Jarisch A, Kamal H, et al.
Dtsch Med Wochenschr
. 2024 Apr;
149(10):579-586.
PMID: 38657597
Sickle cell disease is a rare, but complex multi-systemic disorder with high need of interdisciplinary and specialized care and new structural requirements. Besides care of those chronically sick patients, transition...
3.
Peffault de Latour R, Roth A, Kulasekararaj A, Han B, Scheinberg P, Maciejewski J, et al.
N Engl J Med
. 2024 Mar;
390(11):994-1008.
PMID: 38477987
Background: Persistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or have not received complement inhibitors. Iptacopan,...
4.
Versmold K, Alashkar F, Raiser C, Ofori-Asenso R, Xu T, Liu Y, et al.
Eur J Haematol
. 2023 Mar;
111(1):84-95.
PMID: 36971028
Objective: Describe the real-world clinical profile of eculizumab-treated patients by characterizing their short- and long-term clinical and laboratory outcomes. Methods: This retrospective study used preexisting medical records of eculizumab-treated patients...
5.
Alashkar F, Klump H, Lange C, Proske P, Schussler M, Yamamoto R, et al.
Eur J Haematol
. 2022 Sep;
109(6):664-671.
PMID: 36045599
Paravertebral extramedullary hematopoietic masses (EHMs) account for up to 15% of extramedullary pseudotumors in beta-thalassemia (BT) and are most likely related to compensatory hematopoiesis. In most cases, pseudotumors are incidentally...
6.
Alashkar F, Aramayo-Singelmann C, Boll J, Hoferer A, Jarisch A, Kamal H, et al.
J Pers Med
. 2022 Jul;
12(7).
PMID: 35887653
Sickle cell disease (SCD) is considered a rare disease in Germany. Due to the increasing prevalence, the acute and chronic morbidities associated with the disease and the sharp increase in...
7.
Ullrich F, Hanoun C, Turki A, Liebregts T, Breuckmann K, Alashkar F, et al.
Eur J Haematol
. 2022 Jun;
109(4):364-372.
PMID: 35751531
Introduction: Patients with hematologic disease are at high risk of morbidity and mortality from COVID-19 due to disease-inherent and therapy-related immunodeficiency. Whether infection with the SARS-CoV2 omicron variant leads to...
8.
Aramayo-Singelmann C, Halimeh S, Proske P, Vignalingarajah A, Cario H, Christensen M, et al.
Sci Rep
. 2022 Jun;
12(1):9762.
PMID: 35697769
This monocentric study conducted at the Pediatric and Adult Hemoglobinopathy Outpatient Units of the University Hospital of Essen summarizes the results of hemoglobinopathies diagnosed between August 2018 and September 2021,...
9.
Roth A, Bertram S, Schroeder T, Haverkamp T, Voigt S, Holtkamp C, et al.
Eur J Haematol
. 2022 May;
109(2):186-194.
PMID: 35592930
COVID-19 is a potential life-threatening viral disease caused by SARS-CoV-2 and was declared a pandemic by the WHO in March 2020. mRNA-based SARS-CoV-2 vaccines are routinely recommended in immune-compromised patients,...
10.
Turki A, Tsachakis-Muck N, Leserer S, Crivello P, Liebregts T, Betke L, et al.
Blood Adv
. 2021 Oct;
6(1):28-36.
PMID: 34619756
Cytomegalovirus (CMV) reactivation is a frequent complication after allogeneic hematopoietic cell transplantation (HCT), whose impact on clinical outcome, in particular on leukemic relapse, is controversial. We retrospectively analyzed 687 HCT...